HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants | Zendy

Steven J. Smith | Zendy; Xue Zhi Zhao | Zendy; Terrence R. Burke | Zendy; Stephen H. Hughes | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants

Author(s) -

Steven J. Smith,

Xue Zhi Zhao,

Terrence R. Burke,

Stephen H. Hughes

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01035-18

Subject(s) - integrase , dolutegravir , integrase inhibitor , virology , human immunodeficiency virus (hiv) , drug resistance , mutant , biology , pharmacology , genetics , antiretroviral therapy , viral load , gene

Integrase strand transfer inhibitors (INSTIs) have emerged as clinically effective therapeutics that inhibit HIV-1 replication by blocking the strand transfer reaction catalyzed by HIV-1 integrase (IN). Of the three FDA-approved INSTIs, dolutegravir (DTG) is the least apt to select for resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research